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1. INTRODUCTION {#cas13638-sec-0001}
===============

Protein phosphorylation by protein kinases plays essential roles in signaling pathways that regulate normal cell function, and kinase dysregulation leads to various pathologies, including cancer. Cancer‐related signaling by kinases has been well analyzed, but information relevant to the role of serine/threonine phosphoprotein phosphatases (PPP) in tumor formation remains limited.[1](#cas13638-bib-0001){ref-type="ref"}, [2](#cas13638-bib-0002){ref-type="ref"} Protein phosphatase 6 (PP6) is a PPP consisting of a catalytic (*Ppp6c*) and regulatory subunits.[3](#cas13638-bib-0003){ref-type="ref"} In mammalian cell lines, diverse phenotypes seen following siRNA‐based Ppp6c depletion suggest that PP6 regulates mitosis by dephosphorylating aurora kinase A,[4](#cas13638-bib-0004){ref-type="ref"} activates DNA‐PK to sensitize cells to ionizing radiation,[5](#cas13638-bib-0005){ref-type="ref"}, [6](#cas13638-bib-0006){ref-type="ref"} and is required for homology‐directed double strand repair.[7](#cas13638-bib-0007){ref-type="ref"} PP6 also regulates NFκB signaling by suppressing IkBε degradation in response to TNFα[8](#cas13638-bib-0008){ref-type="ref"} and inactivates TAK1.[9](#cas13638-bib-0009){ref-type="ref"}

Recent DNA sequencing screens relevant to human cancer highlight the importance of PP6 in tumorigenesis. Somatic mutation of *Ppp6c* is reported in approximately 10% of malignant melanomas,[10](#cas13638-bib-0010){ref-type="ref"}, [11](#cas13638-bib-0011){ref-type="ref"} and approximately 20% of skin basal cell carcinomas.[12](#cas13638-bib-0012){ref-type="ref"} In melanoma samples, *Ppp6c* mutations are often accompanied by loss of heterozygosity (LOH) and occur in genomic hot‐spots associated with protein function or stability,[13](#cas13638-bib-0013){ref-type="ref"} suggesting that *Ppp6c* loss is associated with tumor formation. Another important finding is that melanoma tissues harboring *Ppp6c* mutations constitute a different subset than those containing mutations in *pTEN*, a major melanoma suppressor, although both subtypes contain *B‐raf* or *N‐ras* mutations.[10](#cas13638-bib-0010){ref-type="ref"}

We previously assessed *Ppp6c* function in vivo using a skin carcinogenesis mouse model engineered by Hayashi et al[14](#cas13638-bib-0014){ref-type="ref"}. Given that *Ppp6c* null mice exhibit early embryonic lethality,[15](#cas13638-bib-0015){ref-type="ref"} that group engineered mice homozygous for a loxP‐targeted allele on chromosome 4, which, when crossed with *K14Cre* ^*tam*^ mice, undergo Cre‐dependent *Ppp6c* deletion in cytokeratin 14‐positive keratinocytes.[14](#cas13638-bib-0014){ref-type="ref"} In normal skin, a single treatment with 7,12‐dimethylbenz(a)anthracene (DMBA) does not produce papillomas in the absence of tumor promoters[16](#cas13638-bib-0016){ref-type="ref"}; however, we subsequently reported that a single DMBA application was sufficient to generate papillomas in *Ppp6c*‐deficient skin, suggesting that *Ppp6c* loss predisposes cells to DMBA‐induced papilloma formation.[14](#cas13638-bib-0014){ref-type="ref"} Using the same mice, Kato et al[17](#cas13638-bib-0017){ref-type="ref"} reporte that *Ppp6c* loss in mouse keratinocytes increases susceptibility to UVB‐induced carcinogenesis. These latter 2 studies were the first to report that *Ppp6c* loss‐of‐function acts as a tumor promoter in mice.

*K‐ras* activating mutations occur in one‐third of all human cancers.[18](#cas13638-bib-0018){ref-type="ref"} Although oncogenic *K‐ras* functions in tumor initiation and progression, the use of mouse models to define how *K‐ras* targets and activates downstream effectors has been limited. Here, we examined the effect of *Ppp6c* loss on *K‐ras*‐induced proliferation in the context of keratinocyte tumorigenesis. We report that *Ppp6c* deficiency enhances *K‐ras* ^*G12D*^‐dependent tumor promotion.

2. MATERIALS AND METHODS {#cas13638-sec-0002}
========================

2.1. Generation of mice with inducible *Kras* ^*G12D*^ expression and *Ppp6c* deletion {#cas13638-sec-0003}
--------------------------------------------------------------------------------------

Mouse strains, *K14‐CreER* ^*tam*^ (the Jackson Laboratory) and *Ppp6c* ^*flox/flox*^ mice have been described.[14](#cas13638-bib-0014){ref-type="ref"} *LSL‐K‐ras* ^*G12D*^ (a strain of C57BL/6) mice were obtained from the Jackson Laboratory. *K14‐CreER* ^*tam*^ mice were crossed with *LSL‐K‐ras* ^*G12D*^ mice to generate *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ mice, which were then bred with *Ppp6c* ^*flox/flox*^ mice to generate *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/+*^ mice. These mice were further crossed with *Ppp6c* ^*flox/+*^ to generate mice of the following 3 genotypes: *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^, *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ and *K14‐CreER* ^*tam*^ mice. Littermate controls were used in experiments. *Ppp6c* ^*+/−*^ mice were generated as described.[15](#cas13638-bib-0015){ref-type="ref"} All animal experiments were performed with the approval of the Miyagi Cancer Center Research Institute Animal Care and Use Committee.

2.2. 4‐Hydroxytamoxifen treatment {#cas13638-sec-0004}
---------------------------------

4‐Hydroxytamoxifen (4HT) was purchased from Toronto Research Chemicals (North York, Canada). Eight‐week‐old female mice under general isoflurane anesthesia were administered 4HT by ip injection of 0.5 mg 4HT/mouse/d for 5 consecutive days. Control mice were ip‐injected with solvent (corn oil) on the same schedule.

2.3. PCR genotype analysis {#cas13638-sec-0005}
--------------------------

To confirm excision of the loxP‐flanked transcription stop cassette from the *LSL‐K‐ras* ^*G12D*^ allele in DNA from mice treated with 4HT, we used the following primers: (i) 5′‐GTCTTTCCCCAGCACAGTGC‐3′, (ii) 5′‐CTCTTGCCTACGCCAGCT‐3′ and (iii) 5′‐AGCTAGCCACCATGGCTTGAGTAAGTCTGCA‐3′ (Figure [1](#cas13638-fig-0001){ref-type="fig"}A). Cre‐mediated deletion of the *Ppp6c* floxed allele was confirmed as described,[14](#cas13638-bib-0014){ref-type="ref"} using primers (iv) 5′‐TATCACGAGGCCCTTTCG‐3′ and (v) 5′‐TAGTGAACCTCTTCGAGG‐3′ (Figure [1](#cas13638-fig-0001){ref-type="fig"}A).

![*CreER* ^*tam*^‐mediated Kras^G12D^ expression and *Ppp6c* disruption. A, Schematic representation of a K‐ras floxed allele and deletion of the transcription stop sequence by activated *CreER* ^*tam*^. Positions of primers a, b and c are indicated. Schematic representation of the Ppp6c‐floxed allele and deletion of exon 4 by activated *CreER* ^*tam*^. Positions of primers d and e are indicated. ![](CAS-109-2178-g006.jpg "image") indicates loxP sequence ![](CAS-109-2178-g007.jpg "image") (indicates exon sequence. Serrated region indicates vector sequence. B, PCR analysis of genomic DNA to confirm removal of the transcription stop sequence using primers a, b and c. Lanes 1 and 2: genomic DNA obtained from lips of 4HT‐untreated (lane1) and 4HT‐treated (lane 2) *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ mice. Lanes 3 and 4: genomic DNA obtained from lips of 4HT‐untreated (lane 3) and 4HT‐treated (lane 4) *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ mice. Fragments of 650, 622 and 500 bp correspond to the stop sequence‐deleted allele (amplified with primers a and b), wild‐type allele (amplified with primers a and b) and floxed alleles (amplified with primers a and c), respectively. C, PCR analysis of genomic DNA to detect the exon 4‐deleted *Ppp6c* allele using primers d and e. Lane 1: genomic DNA from lips of *Ppp6c* ^*flox/flox*^ mice. Lane 2: genomic DNA from lips of *Ppp6c* ^*+/*−^ mice. Lanes 3 and 4: genomic DNA from lips of 4HT‐untreated (lane 3) and 4HT‐treated (lane 4) *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ mice. Fragments of 768 and 113 bp correspond to floxed and exon 4‐deleted alleles, respectively](CAS-109-2178-g001){#cas13638-fig-0001}

2.4. Histology and immunohistochemistry {#cas13638-sec-0006}
---------------------------------------

After perfusion with PBS to remove blood, lip tissue from tumor and control mice was dissected, fixed overnight in buffered 3.7% formalin at room temperature, transferred to sequential 70%, 80%, 90% and 100% methanol, and embedded in paraffin. Sections were stained with H&E and examined microscopically by 2 pathologists. Images were acquired using an Olympus BX53 microscope (Tokyo, Japan). Unstained serial sections were used for immunohistochemistry with the following antibodies: goat antibody against mouse cytokeratin 14 (sc‐17104, Santa Cruz Biotechnology, Texas, USA); rabbit antibody against mouse Ki67 (790‐4286, Roche, Basel, Switzerland); rabbit antibody against mouse γH2AX (\#9718, Cell Signaling Technology, Danvers, USA); rabbit antibody against mouse p‐Akt (ab38449, Abcam, Cambridge, UK); rabbit antibody against mouse p‐Erk1/2 (\#4370, Cell Signaling Technology); rabbit antibody against mouse p‐Erk1/2 (\#9101, Cell Signaling Technology); rabbit antibody against mouse p‐4EBP1 (\#2855, Cell Signaling Technology); rabbit antibody against mouse p‐S6 protein (\#4858, Cell Signaling Technology); and rabbit antibody against mouse p‐GSK3 (\#9331, Cell Signaling Technology). Immunohistochemistry was performed using the Ventana Discovery XT system (Roche Tissue Diagnostics K. K. Basel, Switzerland).

2.5. Statistical analysis {#cas13638-sec-0007}
-------------------------

Kaplan‐Meier survival curves and corresponding statistical analysis, as well as log‐rank tests, were done using Prism version 7 (GraphPad Software, San Diego, California, USA). Other statistical significance was determined using Student\'s *t* test. *P* \< .05 served as the cut‐off for significance.

3. RESULTS {#cas13638-sec-0008}
==========

3.1. Development of keratinocyte‐specific *K‐ras* ^*G12D*^‐expressing and *Ppp6c*‐deficient mice {#cas13638-sec-0009}
------------------------------------------------------------------------------------------------

To assess the effects of PP6 loss on activated K‐ras‐induced tumorigenesis in keratinocytes, we established *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ mice (exhibiting epidermal‐specific tamoxifen‐inducible *K‐ras* ^*G12D*^ expression plus *Ppp6c* deficiency) and *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ mice (which showed only epidermal‐specific tamoxifen‐inducible *K‐ras* ^*G12D*^ expression) (Figure [1](#cas13638-fig-0001){ref-type="fig"}A). We injected 8‐week‐old double mutant *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ or single‐mutant *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ female mice with 4HT daily for 5 days and then killed them 12 days after the first injection. We then used PCR to examine genomic DNA from lip skin of both groups to confirm Cre‐induced recombination of the floxed *K‐ras* allele (Figure [1](#cas13638-fig-0001){ref-type="fig"}B) and floxed *Ppp6c* alleles (Figure [1](#cas13638-fig-0001){ref-type="fig"}C).

For the floxed *K‐ras* allele, PCR analysis of lip skin genomic DNA of untreated *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ mice and *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ mice using primers a and c revealed a 500‐bp band derived from the floxed allele (Figure [1](#cas13638-fig-0001){ref-type="fig"}A,B). Comparable DNA from both lines of 4HT‐treated mice showed an additional 650‐bp fragment when amplified with primers a and b, indicating excision of the stop signal and *K‐ras* ^*G12D*^ expression (Figure [1](#cas13638-fig-0001){ref-type="fig"}A,B). A 622‐bp PCR fragment representing the wild‐type *K‐ras* allele was also seen in every sample amplified by primers a and b.

For the floxed *Ppp6c* allele, PCR analysis of lip skin genomic DNA from untreated *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ mice using primers d and e showed a 768‐bp band (Figure [1](#cas13638-fig-0001){ref-type="fig"}A,C) derived from the floxed allele. However, genomic DNA from lip skin of 4HT‐treated *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ mice showed an additional 113‐bp fragment, indicative of exon 4 deletion (Figure [1](#cas13638-fig-0001){ref-type="fig"}A,C).

3.2. Development of tumors in *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12*^ */Ppp6c* ^*flox/flox*^ mice {#cas13638-sec-0010}
--------------------------------------------------------------------------------------------------

We next examined the effect of *Ppp6c* deletion on *Kras* ^*G12D*^ expression in a mouse model. To do so, we used 8‐week‐old *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^, *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ and *K14CreER* ^*tam*^ female mice injected for 5 days with 4HT. 4HT‐treated *K14‐CreER* ^*tam*^ mice survived for more than a year, indicating that 4HT itself does not decrease survival (data not shown). Given that preliminary analysis showed that 4HT‐treated *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ mice die approximately 20 days after the first 4HT injection, we killed mice when they had lost 20% of their body weight. All 4HT‐treated *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ mice were killed within 20 days (Figure [2](#cas13638-fig-0002){ref-type="fig"}A). By contrast, 80% of 4HT‐treated *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ mice were alive at 100 days (Figure [2](#cas13638-fig-0002){ref-type="fig"}A), indicating that *Ppp6c* loss accelerates death of 4HT‐treated *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ mice (log‐rank test, *P *\< .001). 4HT‐treated *K14‐CreER* ^*tam*^ */Ppp6c* ^*flox/flox*^ mice survived for longer than a year without overt defects, as described.[14](#cas13638-bib-0014){ref-type="ref"}

![K‐ras^G12D^ plus *Ppp6c* deficiency driven by cytokeratin 14 promoter‐induced tumor formation and early death. *K14‐CreER* ^*tam*^ mice (n = 10), *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ mice (n = 5) and *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ mice (n = 10) were administered 4HT IPip for 5 d and then examined macroscopically daily until day 20, and then every 4 d. A, Percentage of surviving mice. \*\*\**P* \< .001. B, Macroscopic appearance of representative *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ (left) and *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ (right) female mice at day 18 after the first 4HT injection. Panels at right show higher magnification views of lip (Ba), palm of forelimb (Bb), nipples (Bc), external genitalia and anus (Bd), and palm of hindlimb (Be). C, Histological appearance of lip tissue shown in Ba. Note that panel Ca shows hyperkeratotic neoplastic lesion with a wide stromal stalk, while the higher magnification view shown in Cb indicates a hypercellular area in that region (b). In the latter, neoplastic squamous cells exhibit severe nuclear atypia with 6 mitoses, including 2 normal (circled in black) and 4 abnormal cells (circled in white). Abnormal mitoses indicated by an arrow and arrowhead are shown in respective higher magnification images (c) and (d). A chromosomal bridge (\*) is also indicated (Cd). D, Percentage of mice free of macroscopic lip tumors. H&E staining. \*\*\**P *\< .001](CAS-109-2178-g002){#cas13638-fig-0002}

Figure [2](#cas13638-fig-0002){ref-type="fig"}B (lower) shows a representative 4HT‐injected *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ mouse 18 days after the first injection; that animal exhibits tumors on lips, nipples, external genitalia, anus and palms. By contrast, by 20 days, a representative 4HT‐treated *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ mouse does not exhibit tumors (Figure [2](#cas13638-fig-0002){ref-type="fig"}B, upper). Ten independent 4HT‐treated *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ mice developed similar tumors. When we autopsied mice to determine cause of death, we found that the stomachs of most mice contained less food content than did stomachs of 4HT‐treated *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ mice. No tumors were found in organs such as the oral cavity and esophagus, which contains cytokeratin 14‐expressing basal epithelium. Other intra‐abdominal and thoracic organs appeared free of tumors or metastasis based on macroscopic examination. These observations suggest that large lip tumors interfered with feeding and mice became asthenic. Microscopic analysis of lip tumor tissue from the mouse shown in Figure [2](#cas13638-fig-0002){ref-type="fig"}B (lower) indicated hyperkeratotic papillomatous proliferative lesions (Figure [2](#cas13638-fig-0002){ref-type="fig"}Ca). It is noteworthy that a region of squamous cell carcinoma in situ (CIS) within this lesion (Figure [2](#cas13638-fig-0002){ref-type="fig"}Cb) contains 6 mitoses, including 4 abnormal mitoses (Figure [2](#cas13638-fig-0002){ref-type="fig"}Cb‐d). All 7 4HT‐treated *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ mice killed between days 16 to 20 (Figure [2](#cas13638-fig-0002){ref-type="fig"}A) developed hyperkeratotic papillomaous proliferative lesions in lip tissue, and 100% of these lesions contained CIS regions.

The timing of onset of lip tumors, as identified by visual inspection, is shown in Figure [2](#cas13638-fig-0002){ref-type="fig"}D. Tumors starting appeared at 56 days in 4HT‐treated *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ mice but appeared within 8 days in 4HT‐treated *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ mice, suggesting that tumor promotion by *K‐ras* ^*G12D*^ is due to *Ppp6c* loss (log‐rank test, *P *\< .001). In contrast, tumors did not emerge on lips of 4HT‐treated *K14‐CreER* ^*tam*^ */Ppp6c* ^*flox/flox*^ mice for a year (data not shown), in agreement with a previous finding that dorsal skin of *K14CreER* ^*tam*^ */Ppp6c* ^*flox/flox*^ mice treated with 4HT painting is normal.[14](#cas13638-bib-0014){ref-type="ref"} These findings confirm that the tumor‐promoting effect of *Ppp6c* deficiency appears in the presence of *K‐ras* ^*G12D*^.

3.3. *Ppp6c* deficiency enhances *K‐ras* ^*G12D*^ *‐*induced cell proliferation {#cas13638-sec-0011}
-------------------------------------------------------------------------------

To assess cell proliferation in *Ppp6c‐*deficient *K‐ras* ^*G12D*^‐expressing mice, we injected mice with 4HT, killed them 12 days later and then compared lip tissues histochemically with those from *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ and *K14‐CreER* ^*tam*^ mice. Representative tissue samples (Figure [3](#cas13638-fig-0003){ref-type="fig"}A) show comparable H&E staining of lips from 4HT‐treated *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ (middle) and *K14‐CreER* ^*tam*^ (upper) mice, indicating minimal effects of cytokeratin 14 driven *K‐ras* ^*G12D*^ expression. However, 4HT‐treated *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ mice showed epidermal hyperplasia (acanthosis) and hyperkeratosis (Figure [3](#cas13638-fig-0003){ref-type="fig"}Ac,f). We then examined cell size among the 3 genotypes, and for comparison purposes, calculated the area of basal layer cells (Figure [3](#cas13638-fig-0003){ref-type="fig"}Ad‐f). The ratios of cell size in *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ and *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ mice to cell size seen in *K14‐CreER* ^*tam*^ mice were 1.0 and 2.3, showing that the double mutation increases keratinocyte size in the basal layer (Figure [3](#cas13638-fig-0003){ref-type="fig"}B).

![*Ppp6c* deficiency plus Kras^G12D^ overexpression driven by cytokeratin 14 promoter increases keratinocyte cell proliferation and size as well as epidermal thickness. A, Appearance of lips of 4HT‐treated mice. H&E staining at low (a‐c) and high (d‐f) magnification, and immunohistochemistry using anti‐cytokeratin 14 (g‐i) and anti‐Ki67 (j‐l) antibodies. 4HT‐treated mice as described in Figure [2](#cas13638-fig-0002){ref-type="fig"} were killed 12 d after the first 4HT injection. Samples from *K14‐CreER* ^*tam*^ (upper), *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ (middle) and *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ (lower) mice are shown. Scale bar: 500 μm (low magnification) or 100 μm (high magnification). Insets in (d‐i) represent higher magnification images of corresponding boxed areas depicting basal membrane. Arrowheads of anti‐cytokeratin 14 samples show cytokeratin 14‐positive cells. Scale bar: 25 μm. B, Basal cell size in mouse lip skin (left). The area of 1 cell in H&E‐stained samples shown in (A) was measured using Image J 1.57t (NIH, USA). Data are mean values of 100 cells ± SE. \*\*\**P* \< .001. n.s., non‐significant. C, The number of Ki67‐positive cells in mouse lip skin, counted using samples shown in (A). In each sample, Ki67‐positive cells of approximately 1‐mm width in epidermis were counted. Data are means derived from 4 areas in independent samples ± SE. \**P* \< .05. D, Epidermal thickness in mouse lip tissue at indicated times after first 4HT injection. Data are means ± SE derived from 10 areas of 1 representative mouse](CAS-109-2178-g003){#cas13638-fig-0003}

Because *K‐ras* ^*G12D*^ induction in these studies is driven by the cytokeratin 14 promoter, we assessed cytokeratin 14 localization (Figure [3](#cas13638-fig-0003){ref-type="fig"}Ag‐i). As reported, cytokeratin 14 was detected in basal cells of the epidermis in control *K14‐CreER* ^*tam*^ (Figure [3](#cas13638-fig-0003){ref-type="fig"}Ag) and *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ cells (Figure [3](#cas13638-fig-0003){ref-type="fig"}Ah)[19](#cas13638-bib-0019){ref-type="ref"}; however, in double mutants, cytokeratin 14 was not detected in the basal layer but, rather, was distributed in the suprabasal layer, where the number of cytokeratin 14‐positive cells increased (Figure [3](#cas13638-fig-0003){ref-type="fig"}Ai), suggestive of perturbed keratinocyte differentiation. When we counted cells that were positive for the proliferation marker Ki67 (Figure [3](#cas13638-fig-0003){ref-type="fig"}Aj‐l) we found that the ratio of this number in 4HT‐treated *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ and *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ mice to that of control *K14‐CreER* ^*tam*^ mice was 1.6 and 6.1, respectively (Figure [3](#cas13638-fig-0003){ref-type="fig"}C), indicating that cell proliferation induced by *K‐ras* ^*G12D*^ is accelerated by *Ppp6c* deficiency.

To examine lip epidermis growth, we measured tissue thickness at 4, 8 and 12 days after 4HT injection. Lip thickness of 4HT‐treated *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ was almost the same as that of control *K14‐CreER* ^*tam*^ mice within 12 days (Figure [3](#cas13638-fig-0003){ref-type="fig"}D); however, the epidermal thickness of 4HT‐treated *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ mice increased dramatically 12 days after 4HT injection (Figure [3](#cas13638-fig-0003){ref-type="fig"}D). Specifically, the ratio of lip thickness of *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ to that of *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ mice was 2.3, 24 and 42, at days 4, 8 and 12, respectively (Figure [3](#cas13638-fig-0003){ref-type="fig"}D).

3.4. *K‐ras* ^*G12D*^‐positive/*Ppp6c*‐deficient lip skin tissues show enhanced AKT phosphorylation and γH2AX levels {#cas13638-sec-0012}
--------------------------------------------------------------------------------------------------------------------

To define molecular mechanisms underlying early onset papilloma formation in lips of 4HT‐treated *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ mice, we evaluated signaling downstream of K‐ras. Because ERK and AKT are the major K‐ras effectors governing cell proliferation and growth,[18](#cas13638-bib-0018){ref-type="ref"} we examined their phosphorylation levels. As shown in Figure [4](#cas13638-fig-0004){ref-type="fig"}, 12 days after 4HT treatment we observed enhanced AKT phosphorylation at residue T308 in lip tissues from *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ compared to *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ and control *K14‐CreER* ^*tam*^ mice. However, ERK phosphorylation at T202/Y204 did not differ significantly among 4HT‐treated mice of all 3 genotypes, suggesting that *Ppp6c* deficiency has a more predominant effect on AKT phosphorylation. Because AKT activates the cell cycle,[20](#cas13638-bib-0020){ref-type="ref"} enhanced cell cycle progression seen in doubly‐mutant lip skin tissues (Figure [3](#cas13638-fig-0003){ref-type="fig"}C) could be attributable to activated AKT.

![Accumulation of phospho‐AKT‐positive and γH2AX‐positive cells in doubly mutant (Kras^G12D^ plus *Ppp6c* deficiency) keratinocytes. A, Immunohistochemistry of lip samples shown in Figure [3](#cas13638-fig-0003){ref-type="fig"}A using phospho‐ERK (T202/Y204), phosphoƒ‐AKT (T308) and γH2AX (S139) antibodies. Scale bar: 100 μm. Arrowheads in higher magnification insets of anti‐γH2AX samples show γH2AX‐positive cells. Scale bar: 25 μm. B, The number of γH2AX‐positive cells in lip epidermis. γH2AX‐positive cells were counted using samples shown in (A). Staining was evaluated in γH2AX‐positive epidermal cells of 1‐mm width. Data are means ± SE derived from 4 areas in independent samples. \**P* \< .05. n.s., non‐significant](CAS-109-2178-g004){#cas13638-fig-0004}

We next examined the effect of *Ppp6c* deficiency on DNA repair, as it is reported that activated K‐ras induces DNA breaks by inducing reactive oxygen species,[21](#cas13638-bib-0021){ref-type="ref"} and PP6 plays a key role in homology‐directed repair.[22](#cas13638-bib-0022){ref-type="ref"} To monitor double‐strand breaks (DSB) in epidermis, we evaluated the expression of γH2AX, a DSB marker. As shown in Figure [4](#cas13638-fig-0004){ref-type="fig"}, by 12 days after 4HT treatment, lip tissues of *K14‐CreER* ^*tam*^ */LSL‐K‐ras* ^*G12D*^ */Ppp6c* ^*flox/flox*^ mice showed numerous γH2AX‐positive cells in a diffuse pattern in the epidermis. Specifically, the ratio of the number of γH2AX‐positive cells in the *K‐ras* ^*G12D*^ positive and doubly‐mutant (*K‐ras* ^*G12D*^ positive/*Ppp6c*‐deficient) lip to wild type was 6.9 and 76, respectively (Figure [4](#cas13638-fig-0004){ref-type="fig"}B), strongly suggesting that DNA repair is greatly disturbed in doubly‐mutant keratinocytes and that *Ppp6c* loss may enhance DNA breakage primed by mutant *K‐ras* ^*G12D*^.

3.5. *K‐ras* ^*G12D*^‐positive/*Ppp6c*‐deficient lip skin tissues show enhanced activation of AKT‐dependent pathways {#cas13638-sec-0013}
--------------------------------------------------------------------------------------------------------------------

Activated AKT reportedly functions in both cell cycle progression and growth control.[20](#cas13638-bib-0020){ref-type="ref"} As a downstream target of AKT associated with cell growth, we examined phosphorylation of 4EBP1 at T37/46 (Figure [5](#cas13638-fig-0005){ref-type="fig"}), which is a priming phosphorylation site resulted in activation of cap‐dependent translation.[20](#cas13638-bib-0020){ref-type="ref"} We observed phosphorylated 4EBP1 in almost all epidermal tissues in doubly‐mutant (*K‐ras* ^*G12D*^ positive/*Ppp6c‐*deficient) mice. Moreover, when we analyzed phosphorylation of S6 protein at S235/236 by immunohistochemistry, that pattern was similar to that of phosphorylated 4EBP1. These findings suggest that protein synthesis is activated in lip epidermis of doubly‐mutant mice. Finally, we assessed phosphorylation of GSK3, an AKT target and key effector of AKT signaling.[20](#cas13638-bib-0020){ref-type="ref"} As shown in Figure [5](#cas13638-fig-0005){ref-type="fig"}, phosphorylation of GSK3 at S21/9 was upregulated in almost all epidermal tissues in doubly‐mutant mice.

![Accumulation of phospho‐4EBP1, phospho‐S6 and phospho‐GSK3 in doubly mutant (Kras^G12D^ expression with *Ppp6c* deficiency) keratinocytes. Immunohistochemistry of lip samples shown in Figure [3](#cas13638-fig-0003){ref-type="fig"}A, using phospho‐4EBP1 (T37/46), phospho‐S6 (S235/236) and phospho‐GSK3 (S21/9) antibodies. Scale bar: 100 μm](CAS-109-2178-g005){#cas13638-fig-0005}

4. DISCUSSION {#cas13638-sec-0014}
=============

The purpose of this study was to examine the effect of *Ppp6c* loss‐of‐function on mutant K‐ras‐induced tumorigenesis. To do so, we developed mice with an epidermal‐specific inducible double mutation (combining *K‐ras* ^*G12D*^ expression with *Ppp6c* loss) for comparison with K‐ras^G12D^‐expressing mice. Within 12 days of induction, lip tissues of double mutants displayed a hyperplastic epidermis (Figure [3](#cas13638-fig-0003){ref-type="fig"}Af), and on the day of euthanasia, which ranged from 16 to 20 days after induction, animals developed papillomas, some containing focal areas of SCC (Figure [2](#cas13638-fig-0002){ref-type="fig"}Cb). SCC represents the promotion stage in progression of skin carcinogenesis (ie from normal skin, to hyperplastic epidermis, to papilloma, and then to SCC).[16](#cas13638-bib-0016){ref-type="ref"} Single mutant mice harboring only the *K‐ras* ^*G12D*^ transgene did not exhibit these phenotypes, providing evidence that *Ppp6c* deficiency accelerates mutant *K‐ras*‐initiated tumorigenesis in skin tissues. Immunohistochemical analyses of lip tissues further revealed that *Ppp6c* deficiency significantly enhanced AKT phosphorylation initiated by K‐ras^G12D^ (Figure [4](#cas13638-fig-0004){ref-type="fig"}A), whereas an effect of *Ppp6c* deficiency on ERK phosphorylation was absent or minimal, suggesting that AKT itself is a PP6 substrate. It is known that AKT phosphorylated at T308 is a PP2A substrate, but whether PP6 can dephosphorylate this site is not yet known. Some phosphopeptide motifs reportedly become hyper‐phosphorylated in mitotic, Ppp6c‐depleted HeLa cells,[23](#cas13638-bib-0023){ref-type="ref"} but the sequence motif around AKT phospho‐T308 does not fit these. Thus, more information relevant to motifs recognized by PP6 is required. Interestingly, we observed greater accumulation of phospho‐4EBP1 and phospho‐S6, both AKT downstream targets, than that of phospho‐AKT, suggesting that these proteins are also PP6 substrates. The identify of novel PP6 substrates regulating AKT‐pathway remains to be determined.

Epidermal lip tissues from double mutants were approximately 40‐fold thicker than comparable tissues of K‐ras^G12D^ mice by 12 days after induction by tamoxifen treatment (Figure [3](#cas13638-fig-0003){ref-type="fig"}D). Cell proliferation and cell size in these tissues were both upregulated, likely in response to activated AKT. Phosphorylation of 4EBP1 and S6, both downstream of AKT, in these tissues was also enhanced, indicating upregulated protein synthesis. Phosphorylation of GSK3, a direct AKT substrate that functions in cell survival signaling, was also upregulated in these tissues. Taken together, selective activation of AKT by Ppp6c deficiency in the presence of K‐ras^G12D^ may promote epidermal hyperplasia by enhancing both cell proliferation and survival.

*K‐ras* mutations reportedly increase generation of mitochondrial reactive oxygen species in pancreatic acinar cells,[24](#cas13638-bib-0024){ref-type="ref"} and overexpression of mutant N‐ras increases the frequency of DNA damage, leading to increased frequency of error‐prone repair of DSB by nonhomologous end‐joining.[25](#cas13638-bib-0025){ref-type="ref"} Our findings suggest that similar mechanisms may operate in mouse skin. Figure [4](#cas13638-fig-0004){ref-type="fig"}B shows that mutated K‐ras‐induced epidermal γH2AX accumulation, an effect significantly enhanced by *Ppp6c* deficiency, suggesting perturbed DNA stability in doubly mutant tissues. Given reports that PP6 functions in homology directed repair via a DNA‐PK‐dependent mechanism[5](#cas13638-bib-0005){ref-type="ref"}, [6](#cas13638-bib-0006){ref-type="ref"} these data strongly suggest that K‐ras‐induced DNA breaks are not fully repaired in conditions of PP6 deficiency, supporting the idea that *Ppp6c* deficiency accelerates K‐ras^G12D^‐initiated genomic instability.

*K‐ras* is frequently mutated in pancreatic ductal adenocarcinoma (PDA) (approximately 90%), colon and rectal carcinoma (CRC) (approximately 50%) and lung adenocarcinoma (LAC) (approximately 25%).[18](#cas13638-bib-0018){ref-type="ref"} Numerous anti‐Ras reagents have been devised as treatment for PDA, CRC or LAC, but successful therapies remain elusive.[18](#cas13638-bib-0018){ref-type="ref"} It has been shown that in some pathologies, *Ppp6c* is downregulated epigenetically. For example, NF‐κB‐induced miR‐31 downregulates Ppp6c and promotes epidermis hyperproliferation in psoriasis.[26](#cas13638-bib-0026){ref-type="ref"} *Ppp6c* downregulation by miR‐373 may explain why miR‐373 expression can promote proliferation of hepatocellular carcinoma cells.[27](#cas13638-bib-0027){ref-type="ref"} Thus, loss of *Ppp6c* function by upregulation of miRNA that bind to the *Ppp6c* 3′UTR may accelerate formation of K‐ras primed PDA, CRC and LAC.

In conclusion, we have defined synergy between *Ppp6c* deficiency and expression of mutant *K‐ras* in skin tumorigenesis. Highly activated AKT seen in double mutant cells likely plays an important role in epidermal hyperplasia. Future studies should address effects of Ppp6c loss on *K‐ras*‐initiated tumors in cells other than keratinocytes or in the presence of other activated oncogenes.
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